Fate Therapeutics (FATE) Tops Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Fate Therapeutics Reports Second Quarter 2015 Financial Results
August 5, 2015 4:02 PM EDTInterim Data From PROHEMA® PUMA Study Show Reduction in Severe Infections Across Multiple Pathogen Types
First Pediatric Subject Treated in PROHEMA® PROVIDE Study of CNS Cellular Replacement
Strategic Research Collaboration Formed With Juno Therapeutics to Identify Small Molecule Modulators for Programming CAR T and TCR Immunotherapeutics
Two Natural Killer Cell-Based Programs Launched in Collaboration With University of Minnesota for... More
